{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=roflumilast", "query": { "intervention": "roflumilast" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 60, "total_pages": 6, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=roflumilast&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-08T00:40:12.300Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07263230", "title": "The Safety and Efficacy of Roflumilast Foam in HS", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hidradenitis Suppurativa (HS)" ], "interventions": [ { "name": "Roflumilast 0.3% topical foam", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Beth Israel Deaconess Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2026-09-01", "completion_date": "2029-05", "has_results": false, "last_update_posted_date": "2026-07-09", "last_synced_at": "2026-09-08T00:40:12.300Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07263230" }, { "nct_id": "NCT06977711", "title": "Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diffuse Large B-cell Lymphoma" ], "interventions": [ { "name": "Loncastuximab", "type": "DRUG" }, { "name": "Roflumilast", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The University of Texas Health Science Center at San Antonio", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2025-06-20", "completion_date": "2027-04-01", "has_results": false, "last_update_posted_date": "2026-06-22", "last_synced_at": "2026-09-08T00:40:12.300Z", "location_count": 2, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06977711" }, { "nct_id": "NCT06998056", "title": "Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Atopic Dermatitis (Eczema)" ], "interventions": [ { "name": "ARQ-151 cream 0.05%", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arcutis Biotherapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Months", "maximum_age": "2 Years", "sex": "ALL", "summary": "3 Months to 2 Years" }, "enrollment_count": 101, "start_date": "2025-06-09", "completion_date": "2025-12-04", "has_results": false, "last_update_posted_date": "2025-12-10", "last_synced_at": "2026-09-08T00:40:12.300Z", "location_count": 17, "location_summary": "Birmingham, Alabama • Bryant, Arkansas • Fountain Valley, California + 14 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Bryant", "state": "Arkansas" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Rancho Santa Margarita", "state": "California" }, { "city": "Coral Gables", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06998056" }, { "nct_id": "NCT02743377", "title": "PET Imaging of Phosphodiesterase-4 (PDE4) in Brain and Peripheral Organs of McCune-Albright Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Nervous System Disease" ], "interventions": [ { "name": "Brain PET Imaging with 11C Rolipram", "type": "OTHER" }, { "name": "Whole Body PET Baseline with 11C Rolipram", "type": "DRUG" }, { "name": "Whole Body PET Blocked with Roflumilast", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "National Institute of Mental Health (NIMH)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2018-04-04", "completion_date": "2020-05-19", "has_results": true, "last_update_posted_date": "2020-10-19", "last_synced_at": "2026-09-08T00:40:12.300Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02743377" }, { "nct_id": "NCT02363335", "title": "The Role of Phosphodiesterase Inhibitors in Incretin Secretion", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "Placebo", "type": "OTHER" }, { "name": "Roflumilast/Sitagliptin", "type": "OTHER" }, { "name": "Sitagliptin", "type": "OTHER" }, { "name": "Roflumilast", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "National Institute on Aging (NIA)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "21 Years to 55 Years" }, "enrollment_count": 29, "start_date": "2015-02-13", "completion_date": "2016-09-19", "has_results": false, "last_update_posted_date": "2026-07-28", "last_synced_at": "2026-09-08T00:40:12.300Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02363335" }, { "nct_id": "NCT04211389", "title": "Twin Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Plaque Psoriasis" ], "interventions": [ { "name": "ARQ-151 0.3% cream", "type": "DRUG" }, { "name": "ARQ-151 vehicle cream", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arcutis Biotherapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 442, "start_date": "2019-12-17", "completion_date": "2020-11-23", "has_results": true, "last_update_posted_date": "2022-12-07", "last_synced_at": "2026-09-08T00:40:12.300Z", "location_count": 31, "location_summary": "Scottsdale, Arizona • Beverly Hills, California • Encino, California + 26 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Encino", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04211389" }, { "nct_id": "NCT04773587", "title": "Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atopic Dermatitis Eczema" ], "interventions": [ { "name": "Roflumilast Cream 0.15%", "type": "DRUG" }, { "name": "Vehicle Cream", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arcutis Biotherapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": null, "sex": "ALL", "summary": "6 Years and older" }, "enrollment_count": 654, "start_date": "2021-01-27", "completion_date": "2022-08-30", "has_results": true, "last_update_posted_date": "2024-10-09", "last_synced_at": "2026-09-08T00:40:12.300Z", "location_count": 42, "location_summary": "Montgomery, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 37 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Encinitas", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04773587" }, { "nct_id": "NCT00108823", "title": "The HERO-study: Effects of Roflumilast in Patients With COPD (Chronic Obstructive Pulmonary Disease) (BY217/M2-121)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Obstructive Pulmonary Disease, COPD" ], "interventions": [ { "name": "Roflumilast", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 550, "start_date": "2004-10", "completion_date": null, "has_results": false, "last_update_posted_date": "2016-10-26", "last_synced_at": "2026-09-08T00:40:12.300Z", "location_count": 10, "location_summary": "Cities in California, California • Cities in Colorado, Colorado • Cities in Florida, Florida + 7 more", "locations": [ { "city": "Cities in California", "state": "California" }, { "city": "Cities in Colorado", "state": "Colorado" }, { "city": "Cities in Florida", "state": "Florida" }, { "city": "Cities in Missouri", "state": "Missouri" }, { "city": "Cities in New Mexico", "state": "New Mexico" } ], "official_url": "https://clinicaltrials.gov/study/NCT00108823" }, { "nct_id": "NCT01443845", "title": "Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "COPD", "COPD Exacerbation", "Lung Diseases", "Respiratory Disorders", "Pulmonary Disease", "Chronic Obstructive Lung Diseases", "Chronic Obstructive Airway Disease" ], "interventions": [ { "name": "Roflumilast", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 2354, "start_date": "2011-09-30", "completion_date": "2016-01-31", "has_results": true, "last_update_posted_date": "2017-04-13", "last_synced_at": "2026-09-08T00:40:12.300Z", "location_count": 217, "location_summary": "Anniston, Alabama • Athens, Alabama • Florence, Alabama + 175 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Athens", "state": "Alabama" }, { "city": "Florence", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01443845" }, { "nct_id": "NCT00297102", "title": "Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The AURA Study (BY217/M2-124)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Obstructive Pulmonary Disease (COPD)" ], "interventions": [ { "name": "Roflumilast", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 1523, "start_date": "2006-02", "completion_date": "2008-09", "has_results": true, "last_update_posted_date": "2017-01-16", "last_synced_at": "2026-09-08T00:40:12.300Z", "location_count": 47, "location_summary": "Fullerton, California • Los Angeles, California • Palmdale, California + 43 more", "locations": [ { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palmdale", "state": "California" }, { "city": "Rancho Mirage", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00297102" } ] }